Another ongoing trial is exploring the combination of ZW25 + palbociclib + fulvestrant in HER2-positive/HR-positive populations (NCT04224272), with results to be reported at the San Antonio Breast Cancer Symposium in 2022. Here, ERBB2 is linked to breast carcinoma.